Integrin β 1 , osmosensing, and chemoresistance in mouse ehrlich carcinoma cells

Cellular Physiology and Biochemistry

Volumn 36, Issue 1, 2015, Pages 111-132

  Sørensen, Belinda Halling ^a   Rasmussen, Line Jee Hartmann ^a   Broberg, Bjørn Sindballe ^a   Klausen, Thomas Kjær ^a   Sauter, Daniel Peter Rafael ^a   Lambert, Ian Henry ^a   Aspberg, Anders ^a   Hoffmann, Else Kay ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cisplatin; Ehrlich Ascites Tumor Cells; Gemcitabine; Hypotonic cell swelling; Integrin; Multi drug resistance

Indexed keywords

ALPHAVBETA5 INTEGRIN; BETA1 INTEGRIN; CISPLATIN; FIBRONECTIN; GEMCITABINE; SMALL INTERFERING RNA; TAURINE; ANTINEOPLASTIC AGENT; CASPASE; DEOXYCYTIDINE;

ADHERENT CELL; ANIMAL CELL; APOPTOSIS; ARTICLE; CASPASE ASSAY; CELL ADHESION ASSAY; CELL SURVIVAL; CELL SWELLING; CELL VOLUME; COLORIMETRY; COULTER COUNTER; EHRLICH ASCITES TUMOR CELL; ENZYME ACTIVITY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; REAL TIME POLYMERASE CHAIN REACTION; VOLUME; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; CELL ADHESION; CELL PROLIFERATION; CELL SIZE; DRUG EFFECTS; DRUG RESISTANCE; EHRLICH ASCITES TUMOR; GENETICS; METABOLISM; OSMOSIS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD29; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, EHRLICH TUMOR; CASPASES; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SIZE; CISPLATIN; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FIBRONECTINS; MICE; OSMOSIS; TAURINE;

EID: 84928752956     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000374057     Document Type: Article

References (96)

1. Desgrosellier JS, Cheresh DA: Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10:9-22.
2. Brakebusch C, Fassler R: beta 1 integrin function in vivo: adhesion, migration and more. Cancer Metastasis Rev 2005;24:403-411.
3. Schwab A, Stock C: Ion channels and transporters in tumour cell migration and invasion. Philos Trans R Soc Lond B Biol Sci 2014;369:20130102.
4. Barczyk M, Carracedo S, Gullberg D: Integrins. Cell Tissue Res 2010;339:269-280.
5. Aoudjit F, Vuori K: Integrin signaling in cancer cell survival and chemoresistance. Chemother Res Pract 2012;2012:283181.
6. Gilmore AP: Anoikis. Cell Death Differ 2005;12:S1473-1477.
7. Dubois JM, Rouzaire-Dubois B: Roles of cell volume in molecular and cellular biology. Prog Biophys Mol Biol 2012;108:93-97.
8. Pedersen SF, Hoffmann EK, Novak I: Cell volume regulation in epithelial physiology and cancer. Front Physiol 2013;4:233.
9. Hoffmann EK, Lambert IH, Pedersen SF: Physiology of cell volume regulation in vertebrates. Physiol Rev 2009;89:193-277.
10. Lambert IH, Kristensen DM, Holm JB, Mortensen OH: Physiological role of taurine-from organism to organelle. Acta Physiol (Oxf) 2015;213:191-212.
11. Li S, Ault A, Malone CL, Raitt D, Dean S, Johnston LH, Deschenes RJ, Fassler JS: The yeast histidine protein kinase, Sln1p, mediates phosphotransfer to two response regulators, Ssk1p and Skn7p. EMBO J 1998;17:6952-6962.
12. Bahn YS, Kojima K, Cox GM, Heitman J: A unique fungal two-component system regulates stress responses, drug sensitivity, sexual development, and virulence of Cryptococcus neoformans. Mol Biol Cell 2006;17:3122-3135.
13. Pedersen SF, Kapus A, Hoffmann EK: Osmosensory mechanisms in cellular and systemic volume regulation. J Am Soc Nephrol 2011;22:1587-1597.
14. Haussinger D, R. Reinehr, Schliess F: The hepatocyte integrin system and cell volume sensing. Acta Physiol (Oxf) 2006;187:249-255.
15. Vom DS, Schliess F, Reissmann R, Gorg B, Weiergraber O, Kocalkova M, Dombrowski F, Haussinger D: Involvement of integrins in osmosensing and signaling toward autophagic proteolysis in rat liver. J Biol Chem 2003;278:27088-27095.
16. Reinehr R, Sommerfeld A, Haussinger D: Insulin induces swelling-dependent activation of the epidermal growth factor receptor in rat liver. J Biol Chem 2010;285:25904-25912.
17. Artym VV, Petty HR: Molecular proximity of Kv1. 3 voltage-gated potassium channels and beta(1)-integrins on the plasma membrane of melanoma cells: effects of cell adherence and channel blockers. J Gen Physiol 2002;120:29-37.
18. Levite M, Cahalon L, Peretz A, Hershkoviz R, Sobko A, Ariel A, Desai R, Attali B, Lider O: Extracellular K(+) and opening of voltage-gated potassium channels activate T cell integrin function: physical and functional association between Kv1. 3 channels and beta1 integrins. J Exp Med 2000;191:1167-1176.
19. Cahalan MD, Chandy KG: The functional network of ion channels in T lymphocytes. Immunol Rev 2009;231:59-87.
20. Cherubini A, Hofmann G, Pillozzi S, Guasti L, Crociani O, Cilia E, Di SP, Degani S, Balzi M, Olivotto M, Wanke E, Becchetti A, Defilippi P, Wymore R, Arcangeli A: Human ether-a-go-go-related gene 1 channels are physically linked to beta1 integrins and modulate adhesion-dependent signaling. Mol Biol Cell 2005;16:2972-2983.
21. Ren Z, Raucci FJ, Browe DM, Baumgarten CM: Regulation of swelling-activated Cl(-) current by angiotensin II signalling and NADPH oxidase in rabbit ventricle. Cardiovasc Res 2008;77:73-80.
22. Browe DM, Baumgarten CM: EGFR kinase regulates volume-sensitive chloride current elicited by integrin stretch via PI-3K and NADPH oxidase in ventricular myocytes. J Gen Physiol 2006;127:237-251.
23. Browe DM, Baumgarten CM: Angiotensin II (AT1) receptors and NADPH oxidase regulate Cl-current elicited by beta1 integrin stretch in rabbit ventricular myocytes. J Gen Physiol 2004;124:273-287.
24. Browe DM, Baumgarten CM: Stretch of beta 1 integrin activates an outwardly rectifying chloride current via FAK and Src in rabbit ventricular myocytes. J Gen Physiol 2003;122:689-702.
25. Lambert IH, Klausen TK, Bergdahl A, Hougaard C, Hoffmann EK: ROS activate KCl cotransport in nonadherent Ehrlich ascites cells but K+ and Cl-channels in adherent Ehrlich Lettre and NIH3T3 cells. Am J Physiol Cell Physiol 2009;297:C198-C206.
26. Lambert IH: Activation and inactivation of the volume-sensitive taurine leak pathway in NIH3T3 fibroblasts and Ehrlich Lettre ascites cells. Am J Physiol Cell Physiol 2007;293:C390-C400.
27. Koberle B, Tomicic MT, Usanova S, Kaina B: Cisplatin resistance: Preclinical findings and clinical implications. Biochimica et Biophysica Acta-Reviews on Cancer 2010;1806:172-182.
28. Pontiggia O, Sampayo R, Raffo D, Motter A, Xu R, Bissell MJ, Joffe EB, Simian M: The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through beta1 integrin. Breast Cancer Res Treat 2012;133:459-471.
29. Aoudjit F, Vuori K: Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 2001;20:4995-5004.
30. Yang XH, Flores LM, Li Q, Zhou P, Xu F, Krop IE, Hemler ME: Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Res 2010;70:2256-2263.
31. Gutierrez C, Schiff R: HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 2011;135:55-62.
32. Lesniak D, Xu Y, Deschenes J, Lai R, Thoms J, Murray D, Gosh S, Mackey JR, Sabri S, Abdulkarim B: Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. Cancer Res 2009;69:8620-8628.
33. Zhang CJ, Shen ZJ, Pan CW, Zhong S, Li T, Zhang MG: Engagement of integrinbeta1 induces resistance of bladder cancer cells to mitomycin-C. Urology 2012;79:638-643.
34. Thomas F, Holly JM, Persad R, Bahl A, Perks CM: Fibronectin confers survival against chemotherapeutic agents but not against radiotherapy in DU145 prostate cancer cells: involvement of the insulin like growth factor-1 receptor. Prostate 2010;70:856-865.
35. Bhatia V, Mula RV, Weigel NL, Falzon M: Parathyroid hormone-related protein regulates cell survival pathways via integrin alpha6beta4-mediated activation of phosphatidylinositol 3-kinase/Akt signaling. Mol Cancer Res 2009;7:1119-1131.
36. Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, Chilvers ER, Dransfield I, Donnelly SC, Strieter R, Haslett C: Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999;5:662-668.
37. Hodkinson PS, Elliott T, Wong WS, Rintoul RC, Mackinnon AC, Haslett C, Sethi T: ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death Differ 2006;13:1776-1788.
38. Ju L, Zhou C, Li W, Yan L: Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. J Cell Biochem 2010;111:1565-1574.
39. Miyamoto H, Murakami T, Tsuchida K, Sugino H, Miyake H, Tashiro S: Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 2004;28:38-44.
40. Armstrong T, Packham G, Murphy LB, Bateman AC, Conti JA, Fine DR, Johnson CD, Benyon RC, Iredale JP: Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clin Cancer Res 2004;10:7427-7437.
41. Hehlgans S, Haase M, Cordes N: Signalling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta 2007;1775:163-180.
42. Shain KH, Dalton WS: Environmental-mediated drug resistance: a target for multiple myeloma therapy. Expert Rev Hematol 2009;2:649-662.
43. Yao ES, Zhang H, Chen YY, Lee B, Chew K, Moore D, Park C: Increased beta1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res 2007;67:659-664.
44. Oshita F, Kameda Y, Ikehara M, Tanaka G, Yamada K, Nomura I, Noda K, Shotsu A, Fujita A, H. Arai H, Ito H, Nakayama H, Mitsuda A: Increased expression of integrin beta1 is a poor prognostic factor in small-cell lung cancer. Anticancer Res 2002;22:1065-1070.
45. Park CC, Zhang HJ, Yao ES, Park CJ, Bissell MJ: Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res 2008;68:4398-4405.
46. Nielsen K: A hexaploid Ehrlich-Lettre mouse ascites tumor line with low sensitivity to colchicine. Hereditas 1976;83:105-122.
47. Tastesen HS, Holm JB, Moller J, Poulsen KA, Moller C, Sturup S, Hoffmann EK, Lambert IH: Pinpointing differences in cisplatin-induced apoptosis in adherent and non-adherent cancer cells. Cell Physiol Biochem 2010;26:809-820.
48. Poulsen KA, Andersen EC, Hansen CF, Klausen TK, Hougaard C, Lambert IH, Hoffmann EK: Deregulation of apoptotic volume decrease and ionic movements in multidrug-resistant tumor cells: role of chloride channels. Am J Physiol Cell Physiol 2010;298:C14-C25.
49. Bertalanffy FD, Schahter R, Ali J, Ingimundson JC: Mitotic rate and doubling time of intraperitonaeal and subcutaneous Ehrlich ascites tumor cells. Cancer Res 1965;25:685-691.
50. Ozaslan M, Karagoz ID, Kilic IH, Guldur ME: Ehrlich ascites carcinoma. Afr J Biotechnol 2011;10:2375-2378.
51. Dano K: Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 1973;323:466-483.
52. Bellis SL, Newman E, Friedman EA: Steps in integrin beta1-chain glycosylation mediated by TGFbeta1 signaling through Ras. J Cell Physiol 1999;181:33-44.
53. Lambert IH: Reactive oxygen species regulate swelling-induced taurine efflux in NIH3T3 mouse fibroblasts. J Membr Biol 2003;192:19-32.
54. Hubert EM, Musch MW, Goldstein L: Inhibition of volume-stimulated taurine efflux and tyrosine kinase activity in the skate red blood cell. Pflugers Arch 2000;440:132-139.
55. Franco R, Lezama R, Ordaz B, Pasantes-Morales H: Epidermal growth factor receptor is activated by hyposmolarity and is an early signal modulating osmolyte efflux pathways in Swiss 3T3 fibroblasts. Pflugers Arch 2004;447:830-839.
56. Pedersen SF, Beisner KH, Hougaard C, Willumsen BM, Lambert IH, Hoffmann EK: Rho family GTP binding proteins are involved in the regulatory volume decrease process in NIH3T3 mouse fibroblasts. J Physiol 2002;541:779-796.
57. Sun CC, Qu XJ, Gao ZH: Integrins: players in cancer progression and targets in cancer therapy. Anticancer Drugs 2014; doi: 10. 1097/CAD. 0000000000000145.
58. Derynck R, Muthusamy BP, Saeteurn KY: Signaling pathway cooperation in TGF-beta-induced epithelial-mesenchymal transition. Curr Opin Cell Biol 2014;31C:56-66.
59. Takeuchi K, Ito F: Receptor tyrosine kinases and targeted cancer therapeutics. Biol Pharm Bull 2011;34:1774-1780.
60. Martin SS, Vuori K: Regulation of Bcl-2 proteins during anoikis and amorphosis. Biochim Biophys Acta 2004;1692:145-157.
61. Petras M, Lajtos T, Friedlander E, Klekner A, Pintye E, Feuerstein BG, Szollosi J, Vereb G: Molecular interactions of ErbB1 (EGFR) and integrin-beta1 in astrocytoma frozen sections predict clinical outcome and correlate with Akt-mediated in vitro radioresistance. Neuro Oncol 2013;15:1027-1040.
62. Adachi M, Taki T, Higashiyama M, Kohno N, Inufusa H, Miyake M: Significance of integrin alpha5 gene expression as a prognostic factor in node-negative non-small cell lung cancer. Clin Cancer Res 2000;6:96-101.
63. Danen EH, Berge PJT, Van Muijen GN, Van 't Hof-Grootenboer AE, Brocker EB, Ruiter DJ: Emergence of alpha 5 beta 1 fibronectin-and alpha v beta 3 vitronectin-receptor expression in melanocytic tumour progression. Histopathology 1994;24:249-256.
64. Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Heino J, PyrhonenS: Integrin chains beta1 and alphav as prognostic factors in human metastatic melanoma. Melanoma Res 2004;14:29-37.
65. Walter RB, Laszlo GS, Alonzo TA, Gerbing RB, Levy S, Fitzgibbon MP, Gudgeon CJ, Ries RE, Harrington KH, Raimondi SC, Hirsch BA, Gamis AS, McIntosh W, Meshinchi S: Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: a report from the Children's Oncology Group. Am J Hematol 2013;88:694-702
66. Schneller M, Vuori K, Ruoslahti E: Alphavbeta3 integrin associates with activated insulin and PDGFbeta receptors and potentiates the biological activity of PDGF. EMBO J 1997;16:5600-5607.
67. Fujita M, Takada YK, Takada Y: Insulin-like growth factor (IGF) signaling requires alphavbeta3-IGF1-IGF type 1 receptor (IGF1R) ternary complex formation in anchorage independence, and the complex formation does not require IGF1R and Src activation. J Biol Chem 2013;288:3059-3069.
68. Yoon SO, Shin S, Lipscomb EA: A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling. Cancer Res 2006;66:2732-2739.
69. Ramirez NE, Zhang Z, Madamanchi A, Boyd KL, O'Rear LD, Nashabi A, Li Z, Dupont WD, Zijlstra A, Zutter MM: The alpha(2)beta(1) integrin is a metastasis suppressor in mouse models and human cancer. J Clin Invest 2011;121:226-237.
70. Albelda SM: Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest 1993;68:4-17.
71. Zutter MM, Santoro SA, Staatz WD, Tsung YL: Re-expression of the alpha 2 beta 1 integrin abrogates the malignant phenotype of breast carcinoma cells. Proc Natl Acad Sci U S A 1995;92:7411-7415.
72. Shakibaei M, Mobasheri A: Beta1-integrins co-localize with Na, K-ATPase, epithelial sodium channels (ENaC) and voltage activated calcium channels (VACC) in mechanoreceptor complexes of mouse limb-bud chondrocytes. Histol Histopathol 2003;18:343-351.
73. Arcangeli A, Riccarda BMD, Poli R, Ricupero L, Olivotto M: Mutual contact of murine erythroleukemia cells activates depolarizing cation channels, whereas contact with extracellular substrata activates hyperpolarizing Ca2+-dependent K+ channels. J Cell Physiol 1989;139:1-8.
74. Arcangeli A, Becchetti A, Bene MRD, Wanke E, Olivotto M: Fibronectin-integrin binding promotes hyperpolarization of murine erythroleukemia cells. Biochem Biophys Res Commun 1991;177:1266-1272.
75. Becchetti A, Arcangeli A, Bene MRD, Olivotto M, Wanke E: Response to fibronectin-integrin interaction in leukaemia cells: delayed enhancing of a K+ current. Proc Biol Sci 1992;248:235-240.
76. Hofmann G, Bernabei PA, Crociani O, Cherubini A, Guasti L, Pillozzi S, Lastraioli E, Polvani S, Bartolozzi B, Solazzo V, Gragnani L, Defilippi P, Rosati B, Wanke E, Olivotto M, Arcangeli A: HERG K+ channels activation during beta(1) integrin-mediated adhesion to fibronectin induces an up-regulation of alpha(v)beta(3) integrin in the preosteoclastic leukemia cell line FLG 29. 1. J Biol Chem 2001;276:4923-4931.
77. Cherubini A, Hofmann G, Pillozzi S, Guasti L, Crociani O, Cilia E, Di SP, Degani S, Balzi M, Olivotto M, Wanke E, Becchetti A, Defilippi P, Wymore R, Arcangeli A: Human ether-a-go-go-related gene 1 channels are physically linked to beta1 integrins and modulate adhesion-dependent signaling. Mol Biol Cell 2005;16:2972-2983.
78. McPhee JC, Dang YL, Davidson N, LesterHA: Evidence for a functional interaction between integrins and G protein-activated inward rectifier K+ channels. J Biol Chem 1998;273:34696-34702.
79. Arcangeli A, Becchetti A: Integrin structure and functional relation with ion channels. Adv Exp Med Biol 2010;674:1-7.
80. Christensen O, Hoffmann EK: Cell swelling activates K+ and Cl-channels as well as nonselective, stretch-activated cation channels in Ehrlich ascites tumor cells. J Membr Biol 1992;129:13-36.
81. Niemeyer MI, Hougaard C, Hoffmann EK, Jorgensen F, Stutzin A, Sepulveda FV: Characterisation of a cell swelling-activated K+-selective conductance of ehrlich mouse ascites tumour cells. J Physiol 2000;524:757-767.
82. Voss FK, Ullrich F, Munch J, Lazarow K, Lutter D, Mah N, Andrade-Navarro MA, von Kries JP, Stauber T, Jentsch TJ: Identification of LRRC8 heteromers as an essential component of the volume-regulated anion channel VRAC. Science 2014;344:634-638.
83. Qiu Z, Dubin AE, Mathur J, Tu B, Reddy K, Miraglia LJ, Reinhardt J, Orth AP, Patapoutian A: SWELL1, a plasma membrane protein, is an essential component of volume-regulated anion channel. Cell 2014;157:447-458.
84. Abascal F, Zardoya R: LRRC8 proteins share a common ancestor with pannexins, and may form hexameric channels involved in cell-cell communication. Bioessays 2012;34:551-560.
85. Klausen TK, Hougaard C, Hoffmann EK, Pedersen SF: Cholesterol modulates the volume-regulated anion current in Ehrlich-Lettre ascites cells via effects on Rho and F-actin. Am J Physiol Cell Physiol 2006;291:C757-C771.
86. Lambert IH, Hoffmann EK: Cell swelling activates separate taurine and chloride channels in Ehrlich mouse ascites tumor cells. J Membr Biol 1994;142:289-298.
87. Lambert IH: Effect of Arachidonic-Acid, Fatty-Acids, Prostaglandins, and Leukotrienes on Volume Regulation in Ehrlich Ascites Tumor-Cells. J Membr Biol 1987;98:207-221.
88. Lambert IH, Hoffmann EK: The Role of Phospholipase-A2, and 5-Lipoxygenase in the Activation of K and Cl Channels and the Taurine Leak Pathway in Ehrlich Ascites Tumor-Cells. Acta Physiol Scand 1991;143:A33.
89. Villumsen KR, Duelund L, Lambert IH: Acute cholesterol depletion leads to net loss of the organic osmolyte taurine in Ehrlich Lettre tumor cells. Amino Acids 2010;39:1521-1536.
90. Schaller MD: Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. J Cell Sci 2010;123:1007-1013.
91. Zhao J, Guan JL: Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev 2009;28:35-49.
92. Mitra SK, Hanson DA, Schlaepfer DD: Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 2005;6:56-68.
93. Sorensen BH, Thorsteinsdottir UA, Lambert IH: Acquired cisplatin resistance in human ovarian A2780 cancer cells correlates with shift in taurine homeostasis and ability to volume regulate. Am J Physiol Cell Physiol 2014;307:C1071-C1080.
94. Morello V, Cabodi S, Sigismund S, Camacho-Leal MP, Repetto D, Volante M, Papotti M, Turco E, Defilippi P: beta1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells. Oncogene 2011;30:4087-4096.
95. Azreq MAE, Naci D, Aoudjit F: Collagen/beta1 integrin signaling up-regulates the ABCC1/MRP-1 transporter in an ERK/MAPK-dependent manner. Mol Biol Cell 2012;23:3473-3484.
96. Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH: Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 2001;7:1798-1804.